0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV328.57%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.46Leverage Ratio--Theta--Rho--Eff Leverage--Vega
NRX Pharmaceuticals Stock Discussion
HOPE Therapeutics Secures Financing For Ketamine Clinic Expansion
HOPE Therapeutics, Inc., a subsidiary of
https://www.moomoo.com/t/news/post/42897644/mbyzFRmrUf
Benzinga· 1 min ago
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (Nasdaq: NRXP), has announced potential acquisition and financing agreements for $30 million in currently-operating interventional psychiatry clinics. Key points include:
1. A $30 million Term Sheet from a qualifi...
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Second Quarter and Year to Date 2024 Financial Results and Provides Business Update
NRx Pharmaceuticals (NASDAQ:NRXP) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Secured $10.8-$16.3 million in convertible-debt funding to support FDA New Drug Applications for NRX-100(ketamine) and NRX-101.
2. Plans to file NDAs for NRX-100 in suicidal depression and NRX-101 for Acceler...
Set ready
No comment yet